IX Biopharma Ltd
SGX:42C
Operating Margin
IX Biopharma Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| SG |
I
|
IX Biopharma Ltd
SGX:42C
|
15m SGD |
-102%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
721.7B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
186.3B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.3B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
135.5B USD |
27%
|
IX Biopharma Ltd
Glance View
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The firm is focused on the development and commercialization of therapies for diseases of the central nervous system using patent protected formulations for sublingual delivery. The company developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. Its delivery platform is particularly useful for drug repurposing. The firm operates in two segments, namely Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and nutraceutical products. Nutraceutical primary business activities are the sale of nutraceutical products. The firm's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on IX Biopharma Ltd's most recent financial statements, the company has Operating Margin of -102%.
You don't have any saved screeners yet